{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:34:39Z","timestamp":1782128079653,"version":"3.54.5"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Epstein-Barr virus (EBV) infection and posttransplant lymphoproliferative disorders (PTLDs) after pediatric liver transplantation (LT) account for significant morbidity and mortality. Knowledge of EBV kinetics, epidemiology, and outcomes among pediatric living-donor LT cases is largely lacking. This study aims to provide clinical information related to EBV infection, chronic high EBV load (CHL) carriage, and PTLD at a living-donor\u2013dominant pediatric LT center.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>A total of 5827 EBV load measurements from 394 LT recipients fulfilling inclusion criteria and their clinical data were analyzed. EBV loads &gt;1000 copies\/\u03bcg DNA (742 IU\/\u03bcg DNA) were considered \u201chigh,\u201d and CHL was defined by persistence &gt;6 mo.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>The highlighted results were as follows: (1) 94% of recipients underwent living-donor LT; (2) 80% of EBV seronegative recipients developed first EBV infection &lt;2 y post-LT, and their EBV loads were consistently higher than those of seropositive recipients within &lt;3 y post-LT but did not differ thereafter; (3) 61 (15%) recipients met CHL criteria, but none developed PTLD; (4) age &lt;5 y, cytomegalovirus seronegative donors, and early development of EBV DNAemia &lt;6 mo post-LT were independent risk factors for CHL; (5) the incidence of rejections after 1-y post-LT was comparably low among CHL carriers whose immunosuppression was minimized.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Early detection of EBV following LT and CMV seronegative donors would facilitate risk stratification to prevent PTLD while titrating immunosuppression among pediatric LT recipients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000004429","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T16:02:10Z","timestamp":1670428930000},"page":"1322-1329","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Early Detection of Epstein-Barr Virus as a Risk Factor for Chronic High Epstein-Barr Viral Load Carriage at a Living-donor\u2013dominant Pediatric Liver Transplantation Center"],"prefix":"10.1097","volume":"107","author":[{"given":"Masaki","family":"Yamada","sequence":"first","affiliation":[{"name":"Department of Advanced Medicine for Viral Infections, National Center for Child Health and Development, Tokyo, Japan."},{"name":"Department of Medical Subspecialties, Division of Infectious Diseases, National Center for Child Health and Development, Tokyo, Japan."},{"name":"Department of Pediatrics, University of Pittsburgh, School of Medicine and UPMC Children\u2019s Hospital of Pittsburgh, Pittsburgh, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinari","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine for Viral Infections, National Center for Child Health and Development, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Uchida","sequence":"additional","affiliation":[{"name":"Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Yanagi","sequence":"additional","affiliation":[{"name":"Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine for Viral Infections, National Center for Child Health and Development, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seisuke","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mureo","family":"Kasahara","sequence":"additional","affiliation":[{"name":"Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-Ichi","family":"Imadome","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine for Viral Infections, National Center for Child Health and Development, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1128\/JCM.41.11.5245-5249.2003","article-title":"Measurement of Epstein-Barr virus DNA loads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes by competitive PCR.","volume":"41","author":"Wadowsky","year":"2003","journal-title":"J Clin Microbiol"},{"key":"R5-20250604","first-page":"475","article-title":"The biology and clinical utility of EBV monitoring in blood.","volume":"391","author":"Kanakry","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2015-09-672030","article-title":"The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases.","volume":"127","author":"Kanakry","year":"2016","journal-title":"Blood"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"e13652","DOI":"10.1111\/ctr.13652","article-title":"Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: guidelines from the American society of transplantation infectious diseases community of practice.","volume":"33","author":"Allen","year":"2019","journal-title":"Clin Transplant"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/lt.23659","article-title":"Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.","volume":"19","author":"Narkewicz","year":"2013","journal-title":"Liver Transpl"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1111\/j.1600-6143.2005.01002.x","article-title":"Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients.","volume":"5","author":"Lee","year":"2005","journal-title":"Am J Transplant"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1399-3046.2008.00926.x","article-title":"Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients.","volume":"13","author":"Green","year":"2009","journal-title":"Pediatr Transplant"},{"key":"R11-20250604","doi-asserted-by":"crossref","DOI":"10.1111\/petr.12875","article-title":"Epstein-Barr virus DNA monitoring in serum and whole blood in pediatric liver transplant recipients who do or do not discontinue immunosuppressive therapy.","volume":"21","author":"Kullberg-Lindh","year":"2017","journal-title":"Pediatr Transplant"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1600-6143.2007.02080.x","article-title":"Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease\/lymphoma in children.","volume":"8","author":"Bingler","year":"2008","journal-title":"Am J Transplant"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1399-3046.2009.01283.x","article-title":"Chronic high Epstein-Barr viral load carriage in pediatric small bowel transplant recipients.","volume":"14","author":"Lau","year":"2010","journal-title":"Pediatr Transplant"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"e13147","DOI":"10.1111\/petr.13147","article-title":"Epidemiology and outcome of chronic high Epstein-Barr viral load carriage in pediatric kidney transplant recipients.","volume":"22","author":"Yamada","year":"2018","journal-title":"Pediatr Transplant"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/1874303X014070100123","article-title":"Significance of asymptomatic persistent Epstein-Barr viral load in pediatric renal transplant recipients: North American pediatric renal trials and collaborative studies report.","volume":"7","author":"Moudgil","year":"2014","journal-title":"Open Urol Nephrol J"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"e12911","DOI":"10.1111\/tid.12911","article-title":"Risk factors and long-term outcomes of pediatric liver transplant recipients with chronic high Epstein-Barr virus loads.","volume":"20","author":"Kamei","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1016\/j.transproceed.2010.09.134","article-title":"Epstein-Barr virus infection after pediatric living-related liver transplantation--management and risk factors.","volume":"42","author":"Shigeta","year":"2010","journal-title":"Transplant Proc"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1399-3046.2012.01750.x","article-title":"Effective control of Epstein-Barr virus infection following pediatric liver transplantation by monitoring of viral DNA load and lymphocyte surface markers.","volume":"16","author":"Imadome","year":"2012","journal-title":"Pediatr Transplant"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.biologicals.2016.04.010","article-title":"A collaborative study to establish the 1st WHO International Standard for Epstein-Barr virus for nucleic acid amplification techniques.","volume":"44","author":"Fryer","year":"2016","journal-title":"Biologicals"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1097\/TP.0b013e31822d873d","article-title":"A universal preemptive therapy for cytomegalovirus infections in children after live-donor liver transplantation.","volume":"92","author":"Saitoh","year":"2011","journal-title":"Transplantation"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1053\/j.sempedsurg.2017.07.008","article-title":"Pediatric living-donor liver transplantation.","volume":"26","author":"Kasahara","year":"2017","journal-title":"Semin Pediatr Surg"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/ajt.15674","article-title":"OPTN\/SRTR 2018 annual data report: liver.","volume":"20","author":"Kwong","year":"2020","journal-title":"Am J Transplant"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/lt.21595","article-title":"Epstein-Barr virus-associated erythema nodosum after living-donor liver transplantation: a case report.","volume":"15","author":"Yokoyama","year":"2009","journal-title":"Liver Transpl"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/01.tp.0000280544.06865.07","article-title":"Evans syndrome after successful living-donor liver transplantation for neonatal giant cell hepatitis.","volume":"84","author":"Yokoyama","year":"2007","journal-title":"Transplantation"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/ajt.16494","article-title":"OPTN\/SRTR 2019 annual data report: liver.","volume":"21","author":"Kwong","year":"2021","journal-title":"Am J Transplant"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"e13652","DOI":"10.1111\/ctr.13652","article-title":"Post-transplant Lymphoproliferative disorders, EBV infection and disease in solid organ transplantation: guidelines from the American society of transplantation infectious diseases community of practice.","volume":"33","author":"Allen","year":"2019","journal-title":"Clin Transplant"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/j.1600-6143.2006.01394.x","article-title":"CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients.","volume":"6","author":"Green","year":"2006","journal-title":"Am J Transplant"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation.","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice.","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transplant"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1086\/516095","article-title":"Randomized comparison of ganciclovir plus intravenous immune globulin (IVIG) with IVIG alone for prevention of primary cytomegalovirus disease in children receiving liver transplants.","volume":"25","author":"King","year":"1997","journal-title":"Clin Infect Dis"},{"key":"R31-20250604","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1399-3046.2008.01120.x","article-title":"The value of immunoprophylaxis for cytomegalovirus infection with intravenous immunoglobulin in pediatric liver transplant recipients receiving a low-dose immunosupressive regimen.","volume":"14","author":"Krampe","year":"2010","journal-title":"Pediatr Transplant"},{"key":"R32-20250604","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/ajt.15276","article-title":"OPTN\/SRTR 2017 annual data report: liver.","volume":"19","author":"Kim","year":"2019","journal-title":"Am J Transplant"},{"key":"R33-20250604","doi-asserted-by":"crossref","first-page":"e13560","DOI":"10.1111\/petr.13560","article-title":"Immunologic benefit of maternal donors in pediatric living donor liver transplantation.","volume":"23","author":"Kim","year":"2019","journal-title":"Pediatr Transplant"},{"key":"R34-20250604","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/jama.2011.2014","article-title":"Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants.","volume":"307","author":"Feng","year":"2012","journal-title":"Jama"}],"updated-by":[{"DOI":"10.1097\/tp.0000000000004748","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000}}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:11:39Z","timestamp":1749060699000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004429","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,23]]}}}